The history of Redoxis

Redoxis was founded in Sweden in 2007 as an R&D spinout with a focus on preclinical development of small molecules targeting molecular pathways involved in the immunological responses associated with autoimmune diseases. With a core expertise and background in Medical Inflammation Research and preclinical inflammatory models, we decided in 2010 to expand our activities to also encompass CRO services. Since then, our CRO activities have grown significantly, and as of spring 2016, Redoxis has been fully dedicated to providing high-quality CRO services.

Since its inception, Redoxis has built a reputation for scientific excellence, offering specialized in vitro and in vivo models to support drug discovery and early-stage development. Our extensive experience in immunology and translational research has made Redoxis a trusted partner for biotech and pharmaceutical companies worldwide.

Our team of dedicated scientists combines deep disease expertise with cutting-edge methodologies to provide tailored solutions for the characterization of novel therapeutics, including small molecules, biologics, cell and gene therapies, and mRNA-based treatments. Our portfolio includes well-established preclinical models for diseases such as rheumatoid arthritis (RA), multiple sclerosis (MS), Guillain-Barré syndrome (GBS), inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), psoriasis, and acute inflammation. Additionally, we provide tailored solutions for the characterization of novel therapeutic candidates, including viral vector-based and cell and gene therapy approaches.

Over the years, Redoxis has expanded its capabilities to meet the evolving needs of the industry. Our state-of-the-art facilities in Sweden are equipped with advanced technologies to ensure high-quality, reproducible data that drive informed decision-making in drug development.

At the core of Redoxis’ success is a commitment to scientific excellence, collaboration, and innovation. By working closely with our partners, we strive to accelerate the development of effective treatments for patients suffering from chronic and debilitating diseases.

As Redoxis continues to grow, we remain dedicated to advancing preclinical research and delivering scientific solutions that pave the way for future breakthroughs in immunology and beyond.